By Brad Sorensen, CFA
NASDAQ: BBLG
READ THE FULL BBLG RESEARCH REPORT
Bone Biologics Corporation (NASDAQ: BBLG) is entering an increasingly important stage in its development, as the company moves its lead NB1 bone graft candidate through its first human clinical study while demonstrating greater discipline on the corporate expense side. The recently reported second quarter of 2026 provides an encouraging snapshot of that transition: spending is increasingly directed toward product development, general and administrative expenses declined meaningfully year over year, and a financing completed shortly after quarter-end extended the company's expected cash runway into the second quarter of 2027.
A More Focused Cost Structure
For an early-stage medical technology company such as Bone Biologics, the composition of spending can be as important as the absolute level of expenses. The second-quarter numbers showed a favorable shift toward development activities rather than overhead.
General and administrative expenses declined 10.3% year over year, falling to approximately $499,000 in the three months ended June 30, 2026, from approximately $556,000 a year earlier. At the same time, research and development spending increased 61% to approximately $309,000 from $192,000. Management attributed the increase primarily to development work designed to extend the shelf life of its protein.
We view that combination positively. Bone Biologics is reducing administrative costs while increasing expenditures associated with advancing its core technology. Total operating expenses increased approximately 8% to $808,000 during the quarter, but the increase was driven by R&D rather than administrative overhead. The quarterly net loss was approximately $774,000 compared with $741,000 in the prior-year quarter.
The six-month comparison is even more favorable. Operating expenses declined 9.7% to $1.61 million from $1.79 million, while the net loss narrowed 12.4% to approximately $1.54 million from $1.76 million. Cash used in operations was approximately $1.32 million during the first half, slightly below $1.39 million in the comparable 2025 period.
Bone Biologics finished June with approximately $4.03 million in cash. Importantly, that figure does not include the subsequent July private placement, which generated approximately $2.7 million of net proceeds. Management now believes its available capital can support operations into the second quarter of 2027, giving the company additional time to achieve important clinical milestones.
NB1 and the NELL-1 Opportunity
The investment case for BBLG ultimately rests on NB1 and the underlying NELL-1 technology. Bone Biologics is developing NB1 initially as a bone graft product for lumbar spinal fusion. NB1 combines recombinant human NELL-1, or rhNELL-1, with demineralized bone matrix, or DBM. The goal is to provide targeted stimulation of bone regeneration at the site where new bone is needed. The company has exclusive worldwide rights from UCLA to develop and commercialize NELL-1 technology for spinal fusion, osteoporosis, and trauma applications.
What makes NELL-1 particularly interesting is its targeted mechanism. Rather than broadly stimulating bone formation, NELL-1 is designed to act on cells already committed to the bone-forming pathway. In principle, this could provide a more controlled approach to bone growth while reducing the risk of unwanted bone formation in surrounding tissue.
The eventual commercial product is expected to combine purified NELL-1 with an already 510(k)-cleared DBM putty. The protein would be freeze-dried onto DBM and supplied in a kit that allows the surgeon to prepare the material immediately before implantation. Importantly, the company believes NB1 could be incorporated into existing surgical workflows without requiring significant changes in how surgeons prepare or implant an orthobiologic product.
While spinal fusion represents the immediate target, NELL-1 potentially offers a much broader platform opportunity. Bone Biologics' UCLA license covers spinal fusion, osteoporosis and trauma, and management believes the technology ultimately could have applications across multiple orthopedic and bone-regeneration procedures.
Encouraging Preclinical Evidence
The scientific foundation for NB1 has been built over a lengthy period. NELL-1 has been evaluated in laboratory studies and large-animal models, including sheep studies designed to approximate human spinal fusion.
Bone Biologics completed two preclinical sheep studies in which rhNELL-1 promoted bone formation and was reported to be well tolerated without findings of inflammation. Particularly encouraging was the company's pivotal sheep study evaluating rhNELL-1 plus DBM in lumbar interbody fusion. At 26 weeks, the NELL-1 combination demonstrated a 37.5% increase in the frequency of fusion compared with the control group.
Those results do not guarantee success in humans, but they provide an important biological rationale for the current clinical program. The technology has progressed from laboratory work through large-animal testing and has now reached the critical stage of determining whether those results translate into human spinal-fusion patients.
The Human Clinical Trial Could Be the Major Inflection Point
Bone Biologics began treating patients in 2024 in its first-in-human pilot study of NB1. The multicenter, prospective, randomized study in Australia is designed to enroll up to 30 adult patients undergoing transforaminal lumbar interbody fusion for degenerative disc disease. The study evaluates safety and effectiveness, including fusion success, pain, functional improvement and adverse events.
Importantly for the eventual U.S. development pathway, the study design was previously reviewed and agreed upon by the FDA's Division of Orthopedic Devices through the agency's pre-submission process, with the intention that the Australian results support progression to a larger U.S. pivotal trial.
The primary endpoint includes fusion success at 12 months along with change from baseline in the Oswestry Disability Index, a widely used measure of disability associated with lower-back pain. Bone Biologics has indicated that the pilot trial should be completed approximately 12 months after enrollment of the 30th patient. The company has been targeting completion of enrollment by the end of 2026 and has indicated that interim updates may be provided when appropriate.
This creates a potentially important sequence of catalysts. Completion of enrollment would substantially de-risk the operational side of the pilot study. Subsequent safety and fusion data could provide the first meaningful indication of whether the encouraging animal results translate into humans. Positive results would then support the planned larger U.S. pivotal study.
The company has also made progress on manufacturing readiness. Extending the validated shelf life of rhNELL-1 has been an important operational objective because longer stability provides greater flexibility around manufacturing lots, inventory and clinical-trial supply. By July, management said the validated shelf life had reached 29 months, up from 24 months at the end of 2025.
Investment Perspective
Bone Biologics remains a speculative clinical-stage investment, with no commercial revenue and the normal financing, clinical and regulatory risks associated with a small development company. We see the underlying investment story improving. The company has moved NELL-1 from extensive preclinical work into human testing; its pivotal animal study produced encouraging fusion results; the FDA has already reviewed the design of the ongoing pilot study in connection with the path toward a U.S. pivotal trial; and management expects enrollment in the first-in-human study to be completed by year-end. Meanwhile, the latest quarter showed a 10.3% year-over-year reduction in administrative expenses even as R&D spending increased substantially—a combination that suggests capital is increasingly being directed toward advancing the asset that ultimately determines shareholder value.
The July financing further strengthens that setup by extending the expected runway into the second quarter of 2027. That additional capital should give Bone Biologics more time to progress the NB1 clinical program without an immediate financing requirement.
Given the company's relatively early stage and focused capital structure, successful human data followed by advancement into a U.S. pivotal trial could represent a meaningful valuation inflection point, and investors should take a look at BBLG ahead of these potential catalysts.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.